Fig. 6: In vivo inhibition of Cd47 results in a reduction of tumor growth.

A Relative mRNA expression levels of Cd24a and Cd47 in in vitro cultured GCT cells treated with RRX-001, with DMSO-treated GCT cells serving as the control. The result shows that RRX-001 treatment efficiently suppresses Cd47 expression in GCT cells. Data indicate means ± SD, ***p < 0.001, unpaired t test. B Representative morphologies of in vitro cultured GCT cells in DMSO and after RRX-001 treatment, showing that the proliferation of GCT cells was not affected by RRX-001 treatment. The boxed regions in the upper panels are magnified in the lower panels. Scale bar: 100 μm. C The statistical results of cell proliferation during 7 days culture, showing that the proliferation of GCT cells was not affected by RRX-001 treatment. Data represent mean ± SD. D Body weights of vehicle control and RRX-001-treated mice, showing comparable body weights of the RRX-001-treated and control groups. RRX-001 was administrated every two days for three consecutive weeks (n = 9). Data indicate means ± SD. E Representative images of tumors dissected from mice treated with vehicle and RRX-001, illustrating that the GCTs in the RRX-001-treated group were significantly smaller than those in the vehicle control group. F Statistical results of the size and weight of tumors from the vehicle control and RRX-001-treated groups, demonstrating that RRX-001 treatment severely inhibits GCT growth in vivo. G Immunohistochemical staining of CD68 (macrophage marker) in GCT sections from the vehicle control and RRX-001-treated groups, revealing a greater number of invasive CD68 + macrophages in the GCTs from the RRX-001-treated group than from the vehicle control group. Red arrowheads indicate CD68 + macrophages. Scale bar: 100 μm. H Cell density of CD68 + macrophages in indicated groups, confirming the conclusion stated in G. Data indicate means ± SD, **p  <  0.01, unpaired t test.